Genitope Corporation to Host Conference Call to Discuss Updated Blinded Data from Its Phase 3 Clinical Trial

FREMONT, Calif.--(BUSINESS WIRE)--Feb 26, 2007 - Genitope Corporation (Nasdaq:GTOP) today announced that it will be hosting a conference call on Tuesday, February 27, 2007, at 4:30 p.m. (EST) to discuss updated blinded data from its Phase 3 clinical trial of MyVax(R) personalized immunotherapy. The data will be included in a report on Form 8-K to be filed after 4:00 p.m. (EST) on Tuesday, February 27, 2007 with the Securities and Exchange Commission.

The dial-in number for U.S. and Canada is 1-800-260-8140 (passcode 75109878). The international dial-in is 1-617-614-3672 (passcode 75109878). The call can also be accessed in a listen-only mode on Genitope Corporation's Web site at www.genitope.com. The Web cast will be archived for 30 days.

About Genitope Corporation

Genitope Corporation (Fremont, Calif.) is a biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer. Genitope Corporation's lead product candidate, MyVax(R) personalized immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells. For more information on the company, please log on to http://www.genitope.com.

Contact

Investor Contact:
Genitope Corporation
John Vuko, 510-284-3000
IR@genitope.com
or
Media Contact:
Edelman
Marites Cristobal, 323-202-1424
marites.cristobal@edelman.com

Posted: February 2007

Comments